In the biggest biopharma deal since January, Sanofi is bolstering its rare immunology offering by acquiring Blueprint ...

AstraZeneca and Daiichi Sankyo’s Enhertu plus Roche’s Perjeta demonstrated the potential to shake up first-line treatment of ...

South Korean biotech Curogen plans US expansion, adds COO Arvind Sood and board members as it preps for first clinical trial ...

Self-described “blunt pharma executives,” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News ...

BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker ...

Kymera Therapeutics reports positive Phase 1 data for oral drug KT-621, targeting STAT6 as potential competitor to ...

Zetagen Therapeutics, founded 2015, private clinical-stage biopharmaceutical company develops first-of-its-kind targeted ...

AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects ...

Checkpoint therapies like Keytruda, Opdivo, and Imfinzi are expanding from late-stage to early-stage cancer treatment, with ...

Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease ...

Appeals court denies HHS request to pause lower court order blocking federal agency restructuring plans that would cut 10,000 ...

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...